List of insiders holdings for Catalent Inc.:
- Shares directly owned by the insider.
- Shares indirectly owned by the insider.
- Total shares owned by the insider (sum of shares directly and indirectly owned).
- Total market value if available.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Insider Holder Name | Report Date Time | Shares Owned Directly Indirectly | Total Shares Owned | Filing |
Zippelius Peter Director | 2022-10-31 17:46:24 | 11,979 4,330,462 | 4,342,441 | Form 4 |
Chiminski John R Executive Chair | 2022-08-26 20:16:30 | 229,888 0 | 229,888 | Form 4 |
Maselli Alessandro President & CEO | 2024-07-30 16:53:51 | 177,521 0 | 177,521 | Form 4 |
GREISCH JOHN J Executive Chair | 2024-07-30 17:36:18 | 79,932 34,000 | 113,932 | Form 4 |
Gennadios Aristippos Group Pres. Pharma & Consumer | 2024-08-05 12:33:35 | 113,724 0 | 113,724 | Form 4 |
WALSH MATTHEW M EVP & Chief Financial Officer | 2017-08-28 12:29:43 | 103,703 0 | 103,703 | Form 4 |
Joseph Wetteny SVP & Chief Financial Officer | 2021-02-18 09:56:20 | 79,227 0 | 79,227 | Form 4 |
Johnson Sharon See Remarks | 2017-04-27 11:02:19 | 77,645 0 | 77,645 | Form 4 |
Masanovich Matti SVP, Chief Financial Officer | 2024-07-30 16:58:56 | 76,475 0 | 76,475 | Form 4 |
Fasman Steven L EVP & Chief Admin Officer | 2023-12-12 19:11:23 | 75,423 0 | 75,423 | Form 4/A |
Leonard Stephen See Remarks | 2016-07-28 19:21:12 | 73,140 0 | 73,140 | Form 4 |
MOREL DONALD E JR Director | 2024-11-01 17:07:55 | 70,118 0 | 70,118 | Form 4 |
Arnold Jonathan SVP, CCO & Div. Head BioP Del. | 2023-12-12 18:58:20 | 57,573 0 | 57,573 | Form 4/A |
Kurt Nielsen See Remarks | 2015-02-19 19:28:35 | 57,156 0 | 57,156 | Form 4/A |
Dolan Christine SVP - Product Development | 2017-08-31 10:41:26 | 53,736 0 | 53,736 | Form 4 |
STAHL JACK L Director | 2024-11-01 16:48:19 | 47,984 0 | 47,984 | Form 4 |
CLASSON ROLF A Director | 2024-11-01 16:54:23 | 47,984 0 | 47,984 | Form 4 |
Miyamoto Lance SVP, Human Resources | 2019-03-11 19:31:14 | 46,799 0 | 46,799 | Form 4 |
Downie William SVP, Global Sales & Marketing | 2019-02-20 15:48:52 | 46,662 0 | 46,662 | Form 4 |
BUZY PETER L President, Gene Therapy | 2020-04-13 12:12:26 | 45,950 0 | 45,950 | Form 4 |
Littlejohns Barry President, Biologics & SDD | 2019-08-26 15:49:32 | 45,882 0 | 45,882 | Form 4 |
Gunther Scott SVP, Quality & Reg. Affairs | 2024-08-05 12:51:05 | 39,635 0 | 39,635 | Form 4 |
Evoli Lisa SVP, Chief HR Officer | 2024-08-05 12:39:57 | 39,366 0 | 39,366 | Form 4 |
LUCIER GREGORY T Director | 2024-11-01 16:58:54 | 36,914 0 | 36,914 | Form 4 |
McErlane David Group President, Biologics | 2024-09-27 12:01:23 | 36,304 0 | 36,304 | Form 4 |
CARROLL J MARTIN Director | 2024-11-01 17:04:22 | 32,734 0 | 32,734 | Form 4 |
Pravda Ricardo Chief Transformation Officer | 2023-12-12 19:21:40 | 30,982 0 | 30,982 | Form 4/A |
Hopson Ricky Pres. BioProduct Delivery, CoS | 2024-08-05 12:55:50 | 29,974 0 | 29,974 | Form 4 |
Balachandran Madhavan Director | 2023-10-31 17:07:40 | 27,441 0 | 27,441 | Form 4 |
Grippo Michael J SVP, Strategy & Corp. Dev. | 2023-12-12 19:05:25 | 25,229 0 | 25,229 | Form 4/A |
Flynn Karen Director | 2023-10-31 17:00:54 | 24,339 0 | 24,339 | Form 4 |
Ferraro Joseph Anthony SVP, General Counsel, CCO | 2024-10-21 11:30:31 | 23,967 0 | 23,967 | Form 4 |
Crane Rosemary A Director | 2023-10-31 17:02:08 | 23,873 0 | 23,873 | Form 4 |
QUELLA JAMES Director | 2017-08-28 11:31:48 | 20,641 0 | 20,641 | Form 4 |
Castellano Thomas P SVP, Chief Financial Officer | 2022-08-26 20:16:03 | 20,099 0 | 20,099 | Form 4 |
Kreuzburg Christa Director | 2024-01-29 16:09:05 | 18,283 0 | 18,283 | Form 4 |
Barber Michael J Director | 2024-11-01 17:11:14 | 18,052 0 | 18,052 | Form 4 |
Schmidt Kay A SVP, Enterprise Functions | 2022-08-26 20:23:59 | 17,388 0 | 17,388 | Form 4 |
BOOTH MELVIN D Director | 2016-08-26 14:56:50 | 16,665 0 | 16,665 | Form 4 |
Roehrhoff Uwe Director | 2017-11-22 16:25:28 | 16,489 0 | 16,489 | Form 4 |
Houlton Scott See Remarks | 2015-09-04 17:39:27 | 16,380 0 | 16,380 | Form 4 |
Zayas Ricardo SVP, Operations, Biologics NA | 2023-08-03 17:17:23 | 16,101 0 | 16,101 | Form 4 |
Boerman Manja Pres. BioModalities Division | 2023-05-03 19:00:37 | 14,414 0 | 14,414 | Form 4 |
Ryan Michelle R Director | 2024-11-01 17:20:31 | 13,635 0 | 13,635 | Form 4 |
Hatzfeld Michael Chief Accounting Officer | 2024-07-30 17:26:54 | 13,532 0 | 13,532 | Form 4 |
DAMELIO FRANK A Director | 2024-11-01 17:14:21 | 12,635 0 | 12,635 | Form 4 |
Okey Stephanie Director | 2024-11-01 17:17:29 | 12,635 0 | 12,635 | Form 4 |
Barg Steven Director | 2024-11-01 17:23:57 | 12,374 0 | 12,374 | Form 4 |
HEGWOOD PAUL W JR President, CSS | 2019-08-26 15:48:26 | 11,848 0 | 11,848 | Form 4 |
Lickfold Charles SVP, CIO | 2023-12-12 19:19:54 | 11,719 0 | 11,719 | Form 4/A |
Hunt Patricia Pres. Consumer Health Div | 2023-12-12 19:17:51 | 11,501 0 | 11,501 | Form 4/A |
Santiago Karen Murphy VP & Chief Accounting Officer | 2023-08-03 17:21:21 | 9,979 0 | 9,979 | Form 4 |
Carletti Lorenzo SVP Global Ops Ph & Cons Hlth | 2023-12-12 19:09:14 | 9,178 0 | 9,178 | Form 4/A |
Hawkeswood Thomas W Pres. Pharma Prod Delivery Div | 2023-12-12 19:16:02 | 7,827 0 | 7,827 | Form 4/A |
Riley Michael A. Pres. Bio Product Delivery Div | 2022-08-30 14:38:01 | 6,592 0 | 6,592 | Form 4 |
Gargiulo Mario SVP, Ops, Biologics Europe | 2023-05-03 18:58:00 | 5,676 0 | 5,676 | Form 4 |
Whitlow Ricci S President, CSS | 2022-01-24 16:42:46 | 2,923 0 | 2,923 | Form 4 |
Blackstone Management Associates V L.L.C. Blackstone Healthcare Partners L.L.C. BLACKSTONE CAPITAL PARTNERS V L P BMA V L.L.C. Blackstone Holdings III L.P. Blackstone Holdings III GP L.P. Blackstone Holdings III GP Management L.L.C. Blackstone Group L.P. Blackstone Group Management L.L.C. SCHWARZMAN STEPHEN A 10% Owner | 2017-02-14 14:25:56 | 0 0 | 0 | Form 13G |
Chu Chinh Director | 2014-07-31 20:29:59 | 0 0 | 0 | Form 3 |
McEvoy Bruce Director | 2014-07-31 20:19:30 | 0 0 | 0 | Form 3 |